Treatment Effectiveness
Conditions
Keywords
Helicobacter pylori, Vonoprazan, Standard triple therapy, Adolescent, Eradication rate
Brief summary
The trial tends to evaluate the efficacy of vonoprazan-based triple therapy in eradicating H. Pylori infection in adolescent patients in Egypt, in comparison to standard treatment regimens to determine if it offers superior eradication rates (VONTAPE trial).
Detailed description
The VONTAPE trial will compare two treatment regimens for Helicobacter pylori eradication among adolescent patients presented to the gastroenterology department in an Egyptian institute. the eligible subjects will be randomly assigned to one of the two protocols (vonoprazan based vs. proton pump inhibitor-based triple therapy) for two weeks. then the eradication rates will be compared between the two study groups to see if there is a difference in efficacy. The currently available eradication regimens in our country show a low to intermediate eradication rate (50-75%). At the same time, H. pylori infection is prevalent. Recently, the FDA approved vonoprazan-based regimens for adult H. pylori infection with high eradication rates even in the settings of clarithromycin antibiotic resistance. In the VOTSAPE trial, we will test this efficacy in the \< 18 years adolescents.
Interventions
DRUGVonoprazan
an acid suppressor therapy that inhibits the H+, K+-ATPase enzyme system in a potassium-competitive manner.
DRUGAmoxicillin
An antibiotic of penicillins antibiotic group
DRUGClarithromycin
An antibiotic of macrolide group
DRUGEsomeprazole
An acid suppressor therapy that blocks the proton pump.
Sponsors
Alexandria University
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)
Eligibility
Sex/Gender
ALL
Age
10 Years to 18 Years
Healthy volunteers
No
Inclusion criteria
1. Children in the age group (10-18 years), both genders, referred with dyspeptic complaints such as heartburn, dyspepsia, nausea, and epigastric pain. 2. Who is positive for H. Pylori infection by a standardized diagnostic test. 3. Pediatric patients with a clinical, laboratory, and endoscopic diagnosis of H.P.-positive gastritis and the other conditions necessary for H.P. eradication according to the Maastricht V consensus report.
Exclusion criteria
1. allergy to any of the drugs used in the study 2. previous attempts to eradicate H.P. 3. Use of antibiotics, acid-suppression, bismuth, or probiotics 4 weeks before enrollment. 4. Children with conditions that affect medication absorption e.g. celiac or Crohn's disease. 5. Liver or kidney failure. 6. symptoms suggestive of functional disorders.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Helicobacter Pylori eradication rate | 4 weeks after completion of treatment | Number of patients who will test negative for H. pylori after treatment completion. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| The adverse events during therapy | During the treatment duration, and the end of the 2 weeks treatment protocol | Treatment-related adverse effects (TRAEs) such as abdominal discomfort, diarrhea, vomiting, nausea, flatulence, taste disturbance, or loss of appetite, the need for discontinuation of the H. pylori therapy; and/or headache. |
Countries
Egypt
Outcome results
None listed